Mirador Capital Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-15,420
| Closed | -$594K | – | 196 |
|
|
2024
Q2 | $594K | Buy |
15,420
+687
| +5% | +$28.9K | 0.11% | 110 |
|
|
2024
Q1 | $632K | Buy |
14,733
+722
| +5% | +$29.8K | 0.12% | 114 |
|
|
2023
Q4 | $519K | Buy |
14,011
+61
| +0.4% | +$2.19K | 0.11% | 113 |
|
|
2023
Q3 | $506K | Buy |
13,950
+251
| +2% | +$8.91K | 0.12% | 119 |
|
|
2023
Q2 | $488K | Sell |
13,699
-86
| -0.6% | -$3.08K | 0.12% | 123 |
|
|
2023
Q1 | $490K | Buy |
13,785
+2,475
| +22% | +$86.6K | 0.12% | 115 |
|
|
2022
Q4 | $397K | Sell |
11,310
-2,232
| -16% | -$74.3K | 0.09% | 129 |
|
|
2022
Q3 | $399K | Sell |
13,542
-125
| -0.9% | -$4.74K | 0.1% | 132 |
|
|
2022
Q2 | $744K | Buy |
13,667
+879
| +7% | +$48.5K | 0.18% | 89 |
|
|
2022
Q1 | $696K | Buy |
12,788
+2,650
| +26% | +$144K | 0.14% | 107 |
|
|
2021
Q4 | $559K | Buy |
10,138
+222
| +2% | +$11.5K | 0.12% | 131 |
|
|
2021
Q3 | $474K | Buy |
9,916
+12
| +0.1% | +$603 | 0.11% | 140 |
|
|
2021
Q2 | $493K | Buy |
9,904
+452
| +5% | +$21.7K | 0.11% | 138 |
|
|
2021
Q1 | $422K | Sell |
9,452
-445
| -4% | -$20.2K | 0.11% | 126 |
|
|
2020
Q4 | $455K | Buy |
9,897
+91
| +0.9% | +$4.18K | 0.12% | 124 |
|
|
2020
Q3 | $461K | Sell |
9,806
-819
| -8% | -$41K | 0.14% | 111 |
|
|
2020
Q2 | $542K | Buy |
10,625
+61
| +0.6% | +$3.13K | 0.2% | 89 |
|
|
2020
Q1 | $560K | Buy |
10,564
+130
| +1% | +$6.93K | 0.23% | 78 |
|
|
2019
Q4 | $613K | Buy |
10,434
+347
| +3% | +$19.3K | 0.25% | 89 |
|
|
2019
Q3 | $538K | Buy |
10,087
+70
| +0.7% | +$3.6K | 0.24% | 95 |
|
|
2019
Q2 | $501K | Buy |
10,017
+577
| +6% | +$29K | 0.25% | 87 |
|
|
2019
Q1 | $493K | Sell |
9,440
-198
| -2% | -$9.89K | 0.27% | 79 |
|
|
2018
Q4 | $460K | Buy |
9,638
+244
| +3% | +$12K | 0.28% | 75 |
|
|
2018
Q3 | $472K | Sell |
9,394
-100
| -1% | -$5.08K | 0.23% | 86 |
|
|
2018
Q2 | $478K | Hold |
9,494
| – | – | 0.26% | 80 |
|
|
2018
Q1 | $476K | Buy |
9,494
+3,773
| +66% | +$176K | 0.33% | 61 |
|
|
2017
Q4 | $254K | Buy |
5,721
+172
| +3% | +$7.95K | 0.14% | 121 |
|
|
2017
Q3 | $284K | Hold |
5,549
| – | – | 0.17% | 106 |
|
|
2017
Q2 | $281K | Sell |
5,549
-29
| -0.5% | -$1.55K | 0.17% | 106 |
|
|
2017
Q1 | $294K | Buy |
5,578
+578
| +12% | +$29.3K | 0.21% | 98 |
|
|
2016
Q4 | $241K | Buy |
5,000
+257
| +5% | +$12.7K | 0.19% | 110 |
|
|
2016
Q3 | $256K | Sell |
4,743
-80
| -2% | -$4.39K | 0.23% | 90 |
|
|
2016
Q2 | $271K | Sell |
4,823
-17
| -0.4% | -$896 | 0.27% | 83 |
|
|
2016
Q1 | $245K | Buy |
+4,840
| New | +$241K | 0.27% | 80 |
|
Other funds holding GSK
JEST
Mirador Capital Partners's GSK Position: Q3 2024 in Review
Mirador Capital Partners sold out of GSK (GSK) in Q3 2024, closing a stake of 15,420 shares — an estimated $594K sold.
Mirador Capital Partners first reported a position in GSK in Q1 2016 and held it in 34 quarters. The position peaked at $744K in Q2 2022. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.
- Mirador Capital Partners reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
- Mirador Capital Partners sold 15,420 GSK shares in Q3 2024, an estimated $594K.
- Mirador Capital Partners first reported a position in GSK in Q1 2016 and held it in 34 quarters.
- Mirador Capital Partners's GSK position peaked at $744K in Q2 2022.
- 899 funds tracked by Wall St. Rank held GSK as of Q3 2024.
Based on Mirador Capital Partners's 13F filing for Q3 2024, filed 4 Oct 2024.